Fate Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $546.76 million
- Book Value:
- Revenue TTM:
- $96.30 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Fate Therapeutics Inc had its IPO on 2013-10-01 under the ticker symbol FATE.
The company operates in the Healthcare sector and Biotechnology industry. Fate Therapeutics Inc has a staff strength of 551 employees.
Shares of Fate Therapeutics Inc opened at $5.57 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $5.39 - $5.57, and closed at $5.54.
This is a -0.54% slip from the previous day's closing price.
A total volume of 17,427,100 shares were traded at the close of the day’s session.
In the last one week, shares of Fate Therapeutics Inc have increased by +3.55%.
Fate Therapeutics Inc's Key Ratios
Fate Therapeutics Inc has a market cap of $546.76 million, indicating a price to book ratio of 2.8832 and a price to sales ratio of 20.0077.
In the last 12-months Fate Therapeutics Inc’s revenue was $96.30 million with a gross profit of $-224154000 and an EBITDA of $-294628000. The EBITDA ratio measures Fate Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Fate Therapeutics Inc’s operating margin was -320.24% while its return on assets stood at -23.69% with a return of equity of -48.46%.
In Q4, Fate Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 159.9%.
Fate Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fate Therapeutics Inc’s profitability.
Fate Therapeutics Inc stock is trading at a EV to sales ratio of 15.9288 and a EV to EBITDA ratio of -3.6966. Its price to sales ratio in the trailing 12-months stood at 20.0077.
Fate Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $705.56 million
- Total Liabilities
- $114.05 million
- Operating Cash Flow
- Capital Expenditure
- $6.68 million
- Dividend Payout Ratio
Fate Therapeutics Inc ended 2023 with $705.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $705.56 million while shareholder equity stood at $483.94 million.
Fate Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $114.05 million in other current liabilities, 97000.00 in common stock, $-1050804000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $61.33 million and cash and short-term investments were $436.23 million. The company’s total short-term debt was $5,628,000 while long-term debt stood at $0.
Fate Therapeutics Inc’s total current assets stands at $502.07 million while long-term investments were $4.94 million and short-term investments were $374.89 million. Its net receivables were $38.48 million compared to accounts payable of $8.27 million and inventory worth $0.
In 2023, Fate Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $6.68 million.
Comparatively, Fate Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Fate Therapeutics Inc stock is currently trading at $5.54 per share. It touched a 52-week high of $43.12 and a 52-week low of $43.12. Analysts tracking the stock have a 12-month average target price of $8.27.
Its 50-day moving average was $5.98 and 200-day moving average was $19.16 The short ratio stood at 7.37 indicating a short percent outstanding of 0%.
Around 152.4% of the company’s stock are held by insiders while 11212% are held by institutions.
Frequently Asked Questions About Fate Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.